Drug intelligence / Profile preview

IB-01

Development stage: Unknown
Modality: Peptides, Recombinant Proteins and Enzymes

Overview

IB-01, also known as 多肽蛋白免疫提升剂 (Polypeptide Protein Immune Enhancer), is a peptide/protein-based agent under clinical investigation in China for its ability to enhance immune function. The drug is being evaluated for safety and efficacy in boosting immunity, with at least one registered clinical trial (ChiCTR2400082076) focused on its application for immune enhancement. The product appears to be designed as an immunomodulator, likely leveraging the properties of peptides and proteins to stimulate or regulate components of the immune system. Specific molecular targets or detailed mechanisms have not been disclosed in public sources; however, such agents typically act by promoting activation or proliferation of immune cells or by modulating cytokine production[1][2].

Other names: 多肽蛋白免疫提升剂

Beyond the preview

Go deeper on IB-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IB-01.

Explore the full profile